News und Analysen
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
DexCom (DXCM) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
DexCom (NASDAQ: DXCM)Q4 2023 Earnings CallFeb 08, 2024, 4:30 p.m. ET
Operator
Source Fool.com
DexCom (DXCM) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
DexCom (NASDAQ: DXCM)Q4 2023 Earnings CallFeb 08, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market
Prediction: 2 Stocks That Could Trounce the Market
Every investor wants to beat the market, but doing so is notoriously difficult. That's why many settle for matching the performance of some prominent index by buying the appropriate exchange-traded
Prediction: 2 Stocks That Could Trounce the Market
Every investor wants to beat the market, but doing so is notoriously difficult. That's why many settle for matching the performance of some prominent index by buying the appropriate exchange-traded
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the
2 Healthcare Stocks to Buy Hand Over Fist in February
Many investors believe in the January Effect, or the idea that the stock market tends to go on a run during the first month of the year. Whether or not this effect is real, investing in a company
2 Healthcare Stocks to Buy Hand Over Fist in February
Many investors believe in the January Effect, or the idea that the stock market tends to go on a run during the first month of the year. Whether or not this effect is real, investing in a company
2 Healthcare Stocks to Buy Hand Over Fist in February
Many investors believe in the January Effect, or the idea that the stock market tends to go on a run during the first month of the year. Whether or not this effect is real, investing in a company
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood trounced the market in 2020, with her aggressive investing style helping Ark Invest's family of exchange-traded funds outperform. She beat the market again in 2023 after back-to-back
Pfizer's Problems Go Far Beyond Just Declining COVID Revenue
A lot can change on the stock market in just a few years, and Pfizer (NYSE: PFE) is a great example. At the end of 2021, its shares were trading at around $60, and things were looking great for the
Pfizer's Problems Go Far Beyond Just Declining COVID Revenue
A lot can change on the stock market in just a few years, and Pfizer (NYSE: PFE) is a great example. At the end of 2021, its shares were trading at around $60, and things were looking great for the
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q4 2023 Earnings CallFeb 06, 2024, 5:00 p.m. ET
Operator
Source Fool.com
Why Coherus BioSciences Stock Jumped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) climbed 14.9% on Tuesday after the company announced a positive revision to the terms of its loan agreement with Pharmakon Advisors.
In a press release
Centene (CNC) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Centene (NYSE: CNC)Q4 2023 Earnings CallFeb 06, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it's on track to do so again in the field of pain relief. With the latest clinical-trial data
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it's on track to do so again in the field of pain relief. With the latest clinical-trial data
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it's on track to do so again in the field of pain relief. With the latest clinical-trial data
This High-Flying Stock Just Got Some Bad News: Should You Sell?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) ended 2023 with an important regulatory approval. The company's gene-editing therapy for a duo of blood-related disorders, Casgevy, earned the nod
This High-Flying Stock Just Got Some Bad News: Should You Sell?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) ended 2023 with an important regulatory approval. The company's gene-editing therapy for a duo of blood-related disorders, Casgevy, earned the nod